Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder

NCT05423717 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

166

Enrollment

INDUSTRY

Sponsor class

Conditions

Insomnia

Interventions

DRUG: Daridorexant 10 mg
DRUG: Daridorexant 25 mg
DRUG: Daridorexant 50 mg
DRUG: Placebo

Sponsor

Idorsia Pharmaceuticals Ltd.